VSTM verastem.com Net earnings per share growth forecast for next year

Corporate company logo of Verastem Corp (VSTM)

Verastem, Inc. (VSTM) specializes in targeted therapies for lung and ovarian cancer by suppressing resistant tumors. The company's forward EPS dynamics model demonstrates growth potential, with the -3.40 metric serving as the target level. Geopolitical tensions, however, hinder international clinical trials and the supply of biomaterials. The stable operation of leased laboratories and the scheduled launch of R&D processes support the current pace of development.

VSTM: Verastem Oncology Net earnings per one share growth forecast for next year 07/04/2022 - 11/12/2026

Financial and market metric breakdowns for verastem.com (VSTM)

- share price and consensus valuation forecast:
Stock Price Verastem Inc|VSTM - Analyst Consensus Forecast
- market capitalization data:
Market Value Verastem|VSTM - Value Adjusted for Debt and Cash
- company book value details:
Book Value per Share Verastem|VSTM - Book Value of Business|Market Capitalization to Book Value Ratio verastem.com|VSTM - Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Verastem, Inc.|VSTM - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Verastem|VSTM - Company Cumulative Debt|Debts to Book Capitalization Verastem|VSTM - Company Long-Term Indebtedness|Company Current Liabilities Verastem|Quick Liquidity Indicator verastem.com
- earnings and valuation multiples information:
VSTM - Profit After Payment of Taxes|Projected Future Earnings Verastem, Inc.|VSTM - Company Value to Net Income|Forward P/E Multiple Verastem, Inc.|VSTM - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Verastem|VSTM - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Verastem|VSTM - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months verastem.com|VSTM - Earnings per share trend in current year|Expected earnings per share growth for next year Verastem, Inc.
Fundamental company analysis:Verastem Inc, VSTM
Brand item of verastem.com

This indicator reflects the analysts' consensus forecast for the change in net earnings per share, allowing for an assessment of the issuer's future creditworthiness and investment attractiveness. By analyzing the 12-month EPS growth targets, an investor can identify the binary risks of Verastem, Inc. (VSTM), as profit dynamics here depend directly on the outcome of clinical trials for anti-tumor drugs.

Competing companies

GMAB (Genmab US) - Earnings growth forecast for next year|Earnings growth forecast for next year Exelixis Inc.|Net earnings per share growth forecast for next year Nuvalent, Inc. (NUVL)|KYMR (kymeratx.com) - Expected earnings per share trend next year|Earnings growth forecast for next year IDYA (IDEAYA Biosciences, Inc.)|Net earnings per one share growth forecast for next year Enliven Therapeutics Inc|ORIC Pharma - Earnings growth forecast for next year|Expected net earnings per share growth next year Relay Corp|NRIX (Nurix Therapeutics) - Expected earnings per share growth for next year|TYRA: Projected earnings per share increase next year|GLUE (Monte Rosa Therapeutics, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year Cullinan Oncology CGEM|Earnings growth forecast for next year IMRX|C4 Therapeutics Corp - Projected earnings per share growth rate for next year|Black Diamond - Expected earnings per share growth for next year|Expected earnings per share trend next year RPTX|PMVP: Expected earnings per share growth for next year|Karyopharm Therapeutics - Projected earnings per share increase next year|PPCB: Earnings growth forecast for next year|Cyclacel - Expected earnings per share trend next year|AADI (Aadi Bioscience Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Aileron ALRN|Net earnings per share growth forecast for next year Blueprint Medicines (BPMC)|GLYC (glycomimetics.com) - Expected earnings per share trend next year|Earnings growth forecast for next year SWTX (SpringWorks)